# A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine

> **NCT06088745** · PHASE3 · RECRUITING · sponsor: **Beijing Luzhu Biotechnology Co., Ltd.** · enrollment: 4 (estimated)

## Conditions studied

- Vaccine-Preventable Diseases
- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Recombinant Herpes Zoster Vaccine
- **BIOLOGICAL:** Recombinant Herpes Zoster Vaccine Placebo

## Key facts

- **NCT ID:** NCT06088745
- **Lead sponsor:** Beijing Luzhu Biotechnology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-28
- **Primary completion:** 2024-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06088745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06088745, "A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06088745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*